News image

Australian health technology company Global Kinetics Corporation (GKC) has raised AUD$14.8 million to expand its Parkinson’s technology to the US after it was cleared by the Food and Drug Administration.

The company’s lead device, Parkinson’s KinetiGraph, is worn on the patient’s wrist and records movement data – which can then be analysed remotely by clinicians – as well as reminding users when to take their medication.

Andrew Maxwell, managing director of GKC, said: “The first thing we set out to do was to improve the quality of life of people with Parkinson’s.”

The technology was previously available to approximately 50,000 people with Parkinson’s, but the move will increase that number to 1 million.

“We are delivering on our vision to make measurable change to Parkinson’s disease globally,” Maxwell added.